GLP-1 ACCESS · JUNE 2026

Generic Ozempic Has Arrived in Canada

For the first time, Canadians can access generic semaglutide at a fraction of the brand-name price. Here's what happened, why Canada got there first, and where to find it.

What Happened

On June 1, 2026, Health Canada approved the first generic versions of semaglutide (the active ingredient in Ozempic). Multiple manufacturers — led by Sandoz Canada — received approval to market unbranded semaglutide injections, ending Novo Nordisk's Canadian patent monopoly on the drug.

Within days, generic semaglutide began appearing on pharmacy shelves across the country at 50–70% below the brand-name price. Novo Nordisk responded by announcing price cuts on brand-name Ozempic, but the genie is out of the bottle — multiple manufacturers are now competing in what was a single-supplier market just weeks ago.

Why Canada Got Generics First

Canada became the first major market to get generic semaglutide for several reasons:

1. Earlier patent expiry. Semaglutide's Canadian patent protection under the Patent Act and Patented Medicines (Notice of Compliance) Regulations expired earlier than in the United States, where Novo Nordisk holds additional exclusivity periods. The US won't see generic semaglutide until at least 2031–2032.
2. No "evergreening" barriers. Unlike in some jurisdictions, Canadian courts and the Patented Medicine Prices Review Board (PMPRB) have been relatively effective at limiting patent evergreening strategies — where companies file secondary patents on minor formulation changes to extend exclusivity.
3. PMPRB pricing framework. Canada's drug pricing regulator sets ceiling prices for patented medicines. Once generics enter, market competition naturally pushes prices below regulated ceilings, accelerating affordability for patients and provincial formularies.
4. Provincial formulary pressure. Provincial drug plans — which cover millions of Canadians — have been actively pushing for generic alternatives to manage ballooning GLP-1 costs. Several provinces fast-tracked formulary reviews in anticipation of generic availability.

Where to Get Generic Semaglutide

Multiple channels are now available for Canadians seeking generic semaglutide. All require a valid prescription from a Canadian-licensed physician.

Note: This is an informational listing, not an endorsement. Always verify a provider's licensing with your provincial regulatory college. Generic semaglutide requires a prescription — do not purchase from unregulated sources.

What It Costs

Pricing varies by province, pharmacy, and insurance coverage. Here's the landscape as generic competition begins:

Insurance coverage: Most provincial formularies are in the process of adding generic semaglutide. Ontario, BC, and Quebec have confirmed coverage under their public drug plans. Private insurance coverage varies by plan — contact your provider.

What Generic Ozempic Means for Canadians

Short Term (2026)

• Immediate price relief. Patients paying out-of-pocket for Ozempic will see costs drop by 50–70% when switching to authorized generics.
• Supply stabilization. Multiple manufacturers mean more supply. The Ozempic shortages that plagued 2023–2025 should ease significantly.
• Telehealth expansion. Platforms like Felix, Maple, and Livewell are actively onboarding generic semaglutide prescribing. Access through virtual care is faster than ever.

Medium Term (2027–2028)

• Provincial coverage expansion. As prices fall, more provinces will add semaglutide to public formularies for obesity treatment — not just diabetes.
• Price competition deepens. With additional manufacturers entering, generic semaglutide could reach $50–70/month, making it accessible to most Canadians.
• GLP-1 normalization. As generics become ubiquitous, the stigma around GLP-1 use for weight management will continue to decline.

What This Means for Retatrutide

Generic semaglutide sets the stage for the next generation of obesity therapies — including retatrutide, Eli Lilly's triple-agonist currently in Phase 3 trials (TRIUMPH program). As first-generation GLP-1s become generic commodities, the market will shift toward more effective therapies like retatrutide, which has demonstrated up to 30.3% mean weight loss in Phase 3 — significantly surpassing semaglutide's results.

The arrival of generic semaglutide is a win for Canadians today. But it also signals the beginning of a broader shift in how Canada approaches obesity pharmacotherapy — from expensive specialty drugs to accessible, widely-covered treatments.

Sources

• Sandoz sees unbranded versions of Ozempic launching in Canada by end-June 2026 — Reuters
• Ozempic maker cuts price as generic versions hit pharmacy shelves — The Globe and Mail
• Health Canada approves first generic version of Ozempic — CTV News
• Generic semaglutide to hit Canadian pharmacies this week at a fraction of the cost of Ozempic — CBC News
• The era of cheap, generic Ozempic is about to begin — and Canada's the guinea pig — The Logic
• At a fraction of the cost of Ozempic, generic semaglutide to hit Canadian pharmacies this week — BNN Bloomberg

Last updated: June 2, 2026